Skip to content

Study · Randomized controlled trial · n = 47 · 2012

2 results

Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.

Munster PN, Moore AP, Ismail-Khan R, Cox CE, Lacevic M, Gross-King M, Xu P, Carter WB, Minton SE

Journal of clinical oncology : official journal of the American Society of Clinical Oncology9 Jan 2012Cited by 165 (Europe PMC)

PMID22231041 (opens in a new tab)PMCIDPMC3295555 (opens in a new tab)DOI10.1200/jco.2011.34.6890 (opens in a new tab)PepBankPUB-22231041
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In premenopausal breast cancer patients, menstruation resumption did not differ significantly between triptorelin and control during chemotherapy.

    In plain wordsIn premenopausal breast cancer patients, periods resumed at similar rates with triptorelin compared with chemotherapy alone.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeMenstruation resumption
    Study

    n = 47

    Comparator
    chemotherapy without triptorelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Menstruation resumption
    88%
    triptorelin
    Menstruation resumption
    90%
    control

    Source sentences

    Summary
    Menstruation resumed in 19 (90%) of 21 patients in the control group and in 23 (88%) of 26 in the triptorelin group (P= .36).
    1 context sentence
    Summary · context
    Premenopausal women age 44 years or younger were randomly assigned to receive either triptorelin or no triptorelin during (neo)adjuvant chemotherapy and were further stratified by age ( 39 years), estrogen receptor status, and chemotherapy regimen.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In premenopausal breast cancer patients, time to return of menses after chemotherapy did not differ significantly with triptorelin versus control.

    In plain wordsIn premenopausal breast cancer patients, periods returned at similar times with triptorelin compared with chemotherapy alone.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeTime to return of menses
    Study

    n: not reported in source

    Comparator
    chemotherapy without triptorelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Median time to menses
    5.8 months
    triptorelin
    Median time to menses
    5 months
    control

    Source sentences

    Summary
    Menses returned after a median of 5.8 months (range, 1 to 19 months) after completion of chemotherapy in the triptorelin versus 5.0 months (range, 0 to 28 months) in the control arm (P= .58).
    1 context sentence
    Summary · context
    Premenopausal women age 44 years or younger were randomly assigned to receive either triptorelin or no triptorelin during (neo)adjuvant chemotherapy and were further stratified by age ( 39 years), estrogen receptor status, and chemotherapy regimen.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.